CREO - Microwave Ablation Feasibility Study

Part of paid clinical trials in Gilbert, Arizona.

Sponsor
Banner Health
Study ID
NCT07817147
Status
Recruiting
Apply to this trial

Conditions

  • Liver Cancer (Locally Advanced or Metastatic)
  • Liver Cancer Stage IIIa
  • Liver Cancer Stage IIIb
  • Liver Cancer Stage IIIc
  • Liver Cancer Stage IV
  • Pancreatic Cancer
  • Pancreatic Cancer Non-resectable
  • Pancreatic Cancer Stage III
  • Pancreatic Cancer Stage IV

Eligibility Criteria

Sex
ALL
Age
18 Years - N/A
Healthy Volunteers
Not accepted

Interventions

  • EUS-Guided MWA Device — DEVICE
    The rationale of this study is to generate preliminary data on the functionality and safety of Creo's MicroBlate™ Fine device when used under EUS guidance. The results generated from this study will inform any decisions regarding subsequent pivotal trials and may support the integration of this approach into clinical practice for anatomically challenging tumors.

Study Details

The goal of this study is to assess the overall success of energy delivery during treatment using the ultrasound guided microwave ablation device in patients with locally advanced, unresectable, or metastatic cancer. Secondly, this study aims to explore the procedural/clinical safety of treatment with the device and the antitumor effect following treatment with the device.

Key Dates

First listed
Sep 14, 2026
Start date
Feb 19, 2026
Status verified
Sep 2026
Primary completion
Feb 29, 2028
Completion
Aug 31, 2028

Study Design

Enrollment
75 participants (estimated)
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT

Arms

  • Other: Endoscopic Ultrasound (EUS) - Guided Microwave Ablation (MWA) Device Group
    This is a open label feasibility study and only eligible participants will be enrolled into the single arm of the study to receive MWA with this specific device.

Primary Outcome Measure

To assess the success of energy delivery during treatment with the device [ Time Frame: From first MWA procedure to the end of treatment at Week 5 or 9 ]

Central Contacts

Locations (7)

FacilityCityStateZIPSite coordinators
Banner MD Anderson Cancer Center and Gateway HospitalGilbertArizona85234
Neil Sharma, MD
[email protected]
480-256-6444
Cedars SinaiLos AngelesCalifornia90048
Sara Karameh
[email protected]
310-423-6082
Barham Abu Dayyeh, MD (PRINCIPAL_INVESTIGATOR)
Rush University Medical CenterChicagoIllinois60607
Amanda Lin
[email protected]
312-563-3907
Ajay Singh, MD (PRINCIPAL_INVESTIGATOR)
Mayo Clinic RochesterRochesterMinnesota55905
Elizabeth Lemke
[email protected]
507-266-3317
Vinay Chandrasekhara, MD (PRINCIPAL_INVESTIGATOR)
Jad Abimansour, MD (SUB_INVESTIGATOR)
University of Tennessee MedicalKnoxvilleTennessee37920
Brandy Herbert
[email protected]
865-305-5120
Frank Gress, MD (PRINCIPAL_INVESTIGATOR)
Memorial Hermann-Texas Medical CenterHoustonTexas77030
Cecelia Lara
[email protected]
713-500-6529
Nicole Fatheree
[email protected]
Nirav Thosani, MD (PRINCIPAL_INVESTIGATOR)
West Virginia University MedicineMorgantownWest Virginia26506
Chad Glaze
[email protected]
304-293-9195
Shailendra Singh, MD (PRINCIPAL_INVESTIGATOR)

Find similar trials in Gilbert, AZ

Nationwide
Pancreatic cancer trialsOncology trialsGI oncology trials
By condition
Pancreatic cancer
By specialty
OncologyGI oncology
By research site
Banner MD Anderson Cancer Center and Gateway Hospital· Gilbert, AZCedars Sinai· Los Angeles, CARush University Medical Center· Chicago, ILMayo Clinic Rochester· Rochester, MNUniversity of Tennessee Medical· Knoxville, TNMemorial Hermann-Texas Medical Center· Houston, TX

Related Studies